| Literature DB >> 26346823 |
Samira Tajbakhsh1, Kamelya Aliakbari1, Damian J Hussey2, Karen M Lower3, Anthony J Donato4, Elke M Sokoya5.
Abstract
Vascular dysfunction is an early feature of diabetic vascular disease, due to increased oxidative stress and reduced nitric oxide (NO) bioavailability. This can lead to endothelial cell senescence and clinical complications such as stroke. Cells can become senescent by shortened telomeres and oxidative stress is known to accelerate telomere attrition. Sirtuin 1 (SIRT1) has been linked to vascular health by upregulating endothelial nitric oxide synthase (eNOS), suppressing oxidative stress, and attenuating telomere shortening. Accelerated leukocyte telomere attrition appears to be a feature of clinical type 2 diabetes (T2D) and therefore the telomere system may be a potential therapeutic target in preventing vascular complications of T2D. However the effect of T2D on vascular telomere length is currently unknown. We hypothesized that T2D gives rise to shortened leukocyte and vascular telomeres alongside reduced vascular SIRT1 expression and increased oxidative stress. Accelerated telomere attrition was observed in circulating leukocytes, but not arteries, in T2D compared to control rats. T2D rats had blunted arterial SIRT1 and eNOS protein expression levels which were associated with reduced antioxidant defense capacity. Our findings suggest that hyperglycemia and a deficit in vascular SIRT1 per se are not sufficient to prematurely shorten vascular telomeres.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26346823 PMCID: PMC4545169 DOI: 10.1155/2015/153829
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1Timeline depicting the initiation of the assigned diet (high-fat or control diet), administration of streptozotocin or vehicle, blood pressure measurement, and tissue harvesting followed by termination.
Phenotype of control (n = 8) and T2D (n = 6) rats. Values are presented as mean ± standard error of the mean. ∗ indicates P < 0.05 between T2D and control.
| Control | T2D |
| |
|---|---|---|---|
| Weight at injection (g) | 387 ± 5 | 413 ± 9 | 0.029 |
| Final weight (g) | 432 ± 7 | 358 ± 12 | 0.0001 |
| Systolic pressure (mmHg) | 105 ± 5 | 113 ± 5 | 0.15 |
| Glucose (mM) | 8.6 ± 0.3 | 24.2 ± 1.3 | <0.0001 |
| Insulin (ng/mL) | 2.8 ± 0.5 | 0.5 ± 0.1 | 0.0028 |
| Triglycerides (mM) | 1.4 ± 0.1 | 2.0 ± 0.4 | 0.14 |
| Free fatty acids (mM) | 0.34 ± 0.02 | 0.51 ± 0.06 | 0.012 |
| CRP (ng/mL) | 16 ± 0.7 | 263 ± 23 | <0.0001 |
Figure 2(a) Leukocyte T/S ratio was significantly lower in T2D rats compared to control rats (P = 0.034; t-test). Femoral artery T/S ratio was comparable between T2D and control rats (P = 0.28). (b) qPCR products for rat β-actin and telomere primers. Lane 1: DNA ladder; lanes 2 and 6: rat leukocyte calibrator DNA; lanes 3 and 7: control rat leukocyte DNA; lanes 4 and 8: T2D rat leukocyte DNA; lanes 5 and 9: no template control (H2O).
Figure 3Arterial protein expression levels of SIRT1 and eNOS were decreased in T2D rats compared to control rats (n = 3 each; P = 0.0082 and P = 0.011, resp.; t-test). Representative immunoblots are shown below the summary data. Relative protein levels were calculated as the ratio of the intensity of the chemiluminescent bands to the intensity of the total protein loaded on the gel and are expressed as a percentage of the values measured in control rats.
Figure 4Arterial protein expression levels of MnSOD and p66Shc, but not Nox2 or 3-NT, were significantly decreased in T2D rats compared to control rats (n = 3 each; P = 0.039 and P = 0.028, resp.; t-test). Representative immunoblots are shown below the summary data. Relative protein levels were calculated as the ratio of the intensity of the chemiluminescent bands to the intensity of the total protein loaded on the gel and are expressed as a percentage of the values measured in control rats.